Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2b Double Blind, Randomized, Controlled Study of the Safety, Immunogenicity, and Efficacy of Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel® in Young Children in Mali

NCT05776017 is registered in ClinicalTrials.gov with Vac4All as lead sponsor.

NCT NCT05776017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05776017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2b Double Blind, Randomized, Controlled Study of the Safety, Immunogenicity, and Efficacy of Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel® in Young Children in Mali
Lead sponsor
Vac4All
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 27, 2023
Completion date
August 31, 2024
Enrollment
465 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria,falciparum